Targeting DDR1 reshapes the TME, inhibiting chemotherapy resistance induced by the ECM in pancreatic cancer through the DDR1/PYK2/FAK pathway (Ko et al., 2022). This evidence concerns the gene DDR1 and familial pancreatic carcinoma.